ARCHIVES

ODAC Reviews Post-Marketing Studies for Eight Indications

This article is from The Cancer Letter archive.

Vol. 29 No. 12 | March 21, 2003

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Clinical Trials

October 27, 2006

FDA to elevate oncology to office level, consolidate most cancer programs. Search planned for oncologist to head new office.

July 23, 2004

Congressional Committees Add Provisions To Cancer Act Renewal Bills To Strengthen NCI’s Independence, Prevent Fund Withholding

March 8, 1974

FDA Advisors Recommend Approval Of Topotecan for Ovarian Cancer

April 26, 1996

Governors Hear Pitch For State Cancer Control Increased Effort

August 3, 1979

Without Advisor’s Input, Healy Approves Protocol For Gene Therapy

January 15, 1993